8-K: Cencora Reports Strong FY25, Raises Long-Term Guidance

Cencora announced robust fiscal year 2025 results with significant revenue growth and increased adjusted diluted EPS, alongside a dividend hike and raised long-term guidance, despite a GAAP net loss in Q4.

Summary

• Revenue for the fourth quarter of fiscal 2025 increased 5.9 percent year-over-year to $83.7 billion.
• Full fiscal year 2025 revenue increased 9.3 percent year-over-year to $321.3 billion.
• GAAP diluted EPS for the fourth quarter was $(1.75), compared to $0.02 in the prior year quarter.
• Adjusted diluted EPS for the fourth quarter increased 15.0 percent to $3.84.
• GAAP diluted EPS for fiscal year 2025 increased 5.7 percent to $7.96.
• Adjusted diluted EPS for fiscal year 2025 increased 16.3 percent to $16.00.
• The company increased its quarterly dividend by 9 percent to $0.60 per common share.
• Cencora raised its long-term guidance expectations for adjusted diluted EPS and adjusted operating income.
• A $723.9 million goodwill impairment charge related to PharmaLex was recorded in the fourth quarter of fiscal 2025.
• The January 2025 acquisition of Retina Consultants of America (RCA) significantly contributed to gross profit and operating expenses.
• Cencora announced $1 billion in investments through 2030 to strengthen its U.S. distribution network, expand capacity, and increase cold chain storage.
• A new reporting structure will be implemented in fiscal 2026, creating an 'Other' segment for businesses exploring strategic alternatives, including MWI Animal Health, Profarma, U.S. Consulting Services, and parts of PharmaLex.

Sentiment

Score: 8

Explanation: Despite a GAAP net loss in Q4 due to a significant goodwill impairment, the adjusted financial results are very strong, showing double-digit growth in EPS and revenue. The dividend increase, raised long-term guidance, and strategic investments indicate strong management confidence and positive future prospects. The strategic refocusing of the business portfolio also suggests proactive management.

Positives

• Strong revenue growth of 5.9% in Q4 and 9.3% for the full fiscal year 2025.
• Adjusted diluted EPS increased significantly by 15.0% in Q4 and 16.3% for FY2025.
• Quarterly dividend increased by 9% to $0.60 per common share, demonstrating confidence in future cash flows.
• Long-term guidance for adjusted diluted EPS was raised to 9% to 13% growth, and adjusted operating income to 6% to 9% growth.
• The acquisition of Retina Consultants of America (RCA) enhanced the company's position in specialty healthcare.
• U.S. Healthcare Solutions segment operating income grew 25.1% in Q4 and 21.8% for FY2025, driven by market growth and specialty products.
• Planned $1 billion investment through 2030 to strengthen the U.S. distribution network, expanding capacity and cold chain storage for specialty pharmaceuticals.
• Share repurchases reduced diluted shares outstanding by 2.1% in Q4 and 2.5% for FY2025.

Negatives

• GAAP diluted EPS was $(1.75) in the fourth quarter of fiscal 2025, a decrease of $1.77 compared to the prior year quarter.
• A $723.9 million goodwill impairment charge related to PharmaLex significantly impacted GAAP operating expenses and net income in Q4 FY2025.
• GAAP operating income decreased 85.4% in Q4 FY2025 to $18.5 million.
• Net (loss) income attributable to Cencora, Inc. was $(339.7) million in Q4 FY2025, a substantial decline from $3.4 million in the prior year.
• Net interest expense increased by $56.9 million in Q4 FY2025 due to debt issuance for the RCA acquisition and increased revolving credit facility borrowings.
• International Healthcare Solutions segment operating income decreased 2.0% in Q4 and 9.1% for FY2025, partly due to lower operating income at specialized consulting services.

Risks

• Goodwill impairment charges, such as the $723.9 million related to PharmaLex, indicate potential overvaluation or underperformance of acquired assets.
• Increased interest expense due to debt financing for acquisitions and working capital needs could impact future profitability.
• Foreign currency exchange rate fluctuations can negatively impact international segment revenue and operating income, as noted by constant currency adjustments.
• Dependence on LIFO accounting for inventory, which is subject to market and external influences on inventory quantities, product mix, and manufacturer pricing practices.
• Ongoing litigation and opioid-related expenses, although decreased in the current quarter, remain a potential financial burden.
• Acquisition-related deal and integration expenses, particularly from the RCA acquisition, can be substantial and affect short-term profitability.
• The strategic decision to explore alternatives for businesses in the 'Other' segment (MWI Animal Health, Profarma, U.S. Consulting Services, and parts of PharmaLex) carries execution risks related to divestiture or restructuring.

Future Outlook

Cencora projects fiscal year 2026 revenue growth of 5% to 7%, adjusted operating income growth of 8% to 10%, and adjusted diluted EPS in the range of $17.45 to $17.75. The company has also raised its long-term guidance, now expecting adjusted operating income growth of 6% to 9% and adjusted diluted EPS growth of 9% to 13%, reflecting strong confidence in its business fundamentals and strategic execution.

Management Comments

• "Cencora furthered key initiatives in fiscal 2025 to fortify our leading position in healthcare, most notably by enhancing our position in specialty through our acquisition of RCA as well as the decision to strategically refocus our existing business portfolio."
• "Our strategic drivers of prioritizing growth-oriented investments, accelerating digital transformation, cultivating a best-in-class team member culture, and enabling productivity position Cencora to drive value for our stakeholders."
• "As we move into fiscal 2026, we are catalyzing growth and innovation, with our purpose at the core of all we do."
• "Our increased long-term guidance reflects our confidence that Cencora's foundation in pharmaceutical distribution and leading capabilities, coupled with our focused execution will continue driving growth well into the future."

Industry Context

Cencora's strong performance in U.S. Healthcare Solutions, driven by overall market growth, increased sales of specialty products to health systems and physician practices, and products in the GLP-1 class (for diabetes and/or weight loss), indicates the company is effectively capitalizing on key growth trends within the pharmaceutical and healthcare distribution industry. The strategic acquisition of RCA and the planned $1 billion investment in its U.S. distribution network further solidify its commitment to expanding its presence in high-growth specialty pharmaceutical markets.

Corporate Governance

Legal Proceedings

• Litigation and opioid-related expenses were $14.4 million in Q4 FY2025, a decrease compared to the prior year quarter.
• Gains from antitrust litigation settlements were $5.4 million in Q4 FY2025, lower than $62.3 million in the prior year quarter.

Stakeholder Impact

• Shareholders: Benefit from increased dividend, share repurchases, strong adjusted financial performance, and raised long-term guidance. Potential impact from goodwill impairment and strategic alternatives for 'Other' segment.
• Employees: Strategic refocusing and digital transformation initiatives may impact roles and responsibilities. The company aims to cultivate a 'best-in-class team member culture'.
• Customers: Benefit from strengthened U.S. distribution network, expanded capacity, and increased cold chain storage, ensuring reliable delivery of pharmaceuticals and healthcare products.
• Creditors: Impacted by increased debt issuance (senior notes, term loan) to finance acquisitions and working capital, increasing the company's leverage.
• Suppliers: Continued partnership with pharmaceutical innovators across the value chain.

Next Steps

• Host a conference call on November 5, 2025, to discuss the results.
• Attend the Citi Global Healthcare Conference on December 2, 2025.
• Attend the Evercore Healthcare Conference on December 2, 2025.
• Attend the J.P. Morgan Healthcare Conference from January 12-15, 2026.
• Implement a new reporting structure, including an 'Other' segment for businesses exploring strategic alternatives, starting in the first quarter of fiscal 2026.
• Continue $1 billion in investments through 2030 to strengthen the U.S. distribution network.

Key Dates

Recommendation

Cencora delivered robust adjusted financial results for fiscal year 2025, demonstrating strong revenue and EPS growth. The 9% dividend increase and significantly raised long-term guidance signal strong management confidence in future performance. Strategic investments in the U.S. distribution network and the acquisition of RCA position the company well in high-growth specialty pharmaceutical markets. While a GAAP loss occurred in Q4 due to a non-cash goodwill impairment, the underlying operational strength and positive outlook, coupled with proactive portfolio management (strategic review and 'Other' segment for potential divestitures), make this an attractive investment.

Keywords

Cencora, COR, pharmaceutical distribution, healthcare solutions, Q4 2025 earnings, fiscal year 2025, adjusted EPS, GAAP EPS, dividend increase, long-term guidance, Retina Consultants of America, RCA acquisition, PharmaLex, goodwill impairment, U.S. Healthcare Solutions, International Healthcare Solutions, distribution network investment, specialty pharmaceuticals, corporate reorganization